Hauptseite > Publikationsdatenbank > Chemical synthesis of a pore-forming antimicrobial protein, caenopore-5, by using native chemical ligation at a glu-cys site. > print |
001 | 283506 | ||
005 | 20210129222331.0 | ||
024 | 7 | _ | |a 10.1002/cbic.201402513 |2 doi |
024 | 7 | _ | |a pmid:25425108 |2 pmid |
024 | 7 | _ | |a 1439-4227 |2 ISSN |
024 | 7 | _ | |a 1439-7633 |2 ISSN |
024 | 7 | _ | |a WOS:000347780800019 |2 WOS |
024 | 7 | _ | |a altmetric:2929612 |2 altmetric |
037 | _ | _ | |a FZJ-2016-01839 |
041 | _ | _ | |a eng |
082 | _ | _ | |a 540 |
100 | 1 | _ | |a Medini, Karima |0 P:(DE-HGF)0 |b 0 |
245 | _ | _ | |a Chemical synthesis of a pore-forming antimicrobial protein, caenopore-5, by using native chemical ligation at a glu-cys site. |
260 | _ | _ | |a Weinheim |c 2015 |b Wiley-VCH |
336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1457439814_1125 |2 PUB:(DE-HGF) |
336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
336 | 7 | _ | |a ARTICLE |2 BibTeX |
336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
336 | 7 | _ | |a article |2 DRIVER |
520 | _ | _ | |a The 2014 report from the World Health Organization (WHO) on antimicrobial resistance revealed an alarming rise in antibiotic resistance all around the world. Unlike classical antibiotics, with the exception of a few species, no acquired resistance towards antimicrobial peptides (AMPs) has been reported. Therefore, AMPs represent leads for the development of novel antibiotics. Caenopore-5 is constitutively expressed in the intestine of the nematode Caenorhabditis elegans and is a pore-forming AMP. The protein (82 amino acids) was successfully synthesised by using Boc solid-phase peptide synthesis and native chemical ligation. No γ-linked by-product was observed despite the use of a C-terminal Glu-thioester. The folding of the synthetic protein was confirmed by (1) H NMR spectroscopy and circular dichroism and compared with data recorded for recombinant caenopore-5. The permeabilisation activities of the protein and of shortened analogues were evaluated. |
536 | _ | _ | |a 553 - Physical Basis of Diseases (POF3-553) |0 G:(DE-HGF)POF3-553 |c POF3-553 |f POF III |x 0 |
588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
650 | _ | 7 | |a Anti-Infective Agents |2 NLM Chemicals |
650 | _ | 7 | |a Caenorhabditis elegans Proteins |2 NLM Chemicals |
650 | _ | 7 | |a Recombinant Proteins |2 NLM Chemicals |
700 | 1 | _ | |a Harris, Paul W R |0 P:(DE-HGF)0 |b 1 |
700 | 1 | _ | |a Hards, Kiel |0 P:(DE-HGF)0 |b 2 |
700 | 1 | _ | |a Dingley, Andrew |0 P:(DE-Juel1)145681 |b 3 |u fzj |
700 | 1 | _ | |a Cook, Gregory M |0 P:(DE-HGF)0 |b 4 |
700 | 1 | _ | |a Brimble, Margaret A |0 P:(DE-HGF)0 |b 5 |e Corresponding author |
773 | _ | _ | |a 10.1002/cbic.201402513 |g Vol. 16, no. 2, p. 328 - 336 |0 PERI:(DE-600)2020469-3 |n 2 |p 328 - 336 |t ChemBioChem |v 16 |y 2015 |x 1439-4227 |
856 | 4 | _ | |y Restricted |u https://juser.fz-juelich.de/record/283506/files/Medini%20et%20al_2015.pdf |
856 | 4 | _ | |y Restricted |x icon |u https://juser.fz-juelich.de/record/283506/files/Medini%20et%20al_2015.gif?subformat=icon |
856 | 4 | _ | |y Restricted |x icon-1440 |u https://juser.fz-juelich.de/record/283506/files/Medini%20et%20al_2015.jpg?subformat=icon-1440 |
856 | 4 | _ | |y Restricted |x icon-180 |u https://juser.fz-juelich.de/record/283506/files/Medini%20et%20al_2015.jpg?subformat=icon-180 |
856 | 4 | _ | |y Restricted |x icon-640 |u https://juser.fz-juelich.de/record/283506/files/Medini%20et%20al_2015.jpg?subformat=icon-640 |
856 | 4 | _ | |y Restricted |x pdfa |u https://juser.fz-juelich.de/record/283506/files/Medini%20et%20al_2015.pdf?subformat=pdfa |
909 | C | O | |o oai:juser.fz-juelich.de:283506 |p VDB |
910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)145681 |
913 | 1 | _ | |a DE-HGF |b Key Technologies |l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences |1 G:(DE-HGF)POF3-550 |0 G:(DE-HGF)POF3-553 |2 G:(DE-HGF)POF3-500 |v Physical Basis of Diseases |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |
914 | 1 | _ | |y 2016 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CHEMBIOCHEM : 2014 |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
915 | _ | _ | |a No Authors Fulltext |0 StatID:(DE-HGF)0550 |2 StatID |
915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
920 | _ | _ | |l yes |
920 | 1 | _ | |0 I:(DE-Juel1)ICS-6-20110106 |k ICS-6 |l Strukturbiochemie |x 0 |
980 | _ | _ | |a journal |
980 | _ | _ | |a VDB |
980 | _ | _ | |a UNRESTRICTED |
980 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
981 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
Library | Collection | CLSMajor | CLSMinor | Language | Author |
---|